Assignee
SIGNAL PHARM LLC
US103 patents
Top patents by PatentIndex Score
US9512124B2Dec 6, 2016
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC32 citations96
US7129242B2Oct 31, 2006
Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
SIGNAL PHARM LLC59 citations96
US7981893B2Jul 19, 2011
Heteroaryl compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC90 citations94
US9814713B2Nov 14, 2017
Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
SIGNAL PHARM LLC14 citations92
US9365524B2Jun 14, 2016
Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
SIGNAL PHARM LLC22 citations92
US7759342B2Jul 20, 2010
Methods of treatment and prevention using haloaryl substituted aminopurines
SIGNAL PHARM LLC35 citations92
US9737541B2Aug 22, 2017
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC12 citations91
US9701643B2Jul 11, 2017
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC19 citations91
US8383634B2Feb 26, 2013
Methods of treatment using heteroaryl compounds and compositions thereof
SIGNAL PHARM LLC46 citations91
US8372976B2Feb 12, 2013
Methods of treatment comprising the administration of heteroaryl compounds
SIGNAL PHARM LLC40 citations91
US7723340B2May 25, 2010
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC46 citations91
US7521446B2Apr 21, 2009
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC39 citations91
US7220771B2May 22, 2007
Methods of using indazole derivatives as JNK inhibitors
SIGNAL PHARM LLC22 citations91
US7211594B2May 1, 2007
Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
SIGNAL PHARM LLC23 citations91
US7208513B2Apr 24, 2007
Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
SIGNAL PHARM LLC16 citations91
US7122544B2Oct 17, 2006
Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
SIGNAL PHARM LLC20 citations90
US6987184B2Jan 17, 2006
Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related
SIGNAL PHARM LLC19 citations90
US9796685B2Oct 24, 2017
Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-Methylcyclohexylamino)-pyrimidine-5-carboxamide
SIGNAL PHARM LLC14 citations89
US9198866B2Dec 1, 2015
Pharmaceutical formulations of a substituted diaminopurine
SIGNAL PHARM LLC15 citations89
US9187479B2Nov 17, 2015
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC17 citations89
US7968556B2Jun 28, 2011
Heteroaryl compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC41 citations89
US7429599B2Sep 30, 2008
Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
SIGNAL PHARM LLC12 citations84
US10919865B2Feb 16, 2021
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC3 citations83
US10266500B2Apr 23, 2019
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC5 citations83
US10040770B2Aug 7, 2018
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC7 citations83
US9771371B2Sep 26, 2017
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC4 citations83
US9505764B2Nov 29, 2016
Treatment of cancer with dihydropyrazino-pyrazines
SIGNAL PHARM LLC11 citations83
US9493466B2Nov 15, 2016
Treatment of cancer with TOR kinase inhibitors
SIGNAL PHARM LLC7 citations83
US9474757B2Oct 25, 2016
Methods for treating cancer using TOR kinase inhibitor combination therapy
SIGNAL PHARM LLC16 citations83
US9375443B2Jun 28, 2016
Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
SIGNAL PHARM LLC12 citations83
US9358232B2Jun 7, 2016
Methods for treating cancer using TOR kinase inhibitor combination therapy
SIGNAL PHARM LLC13 citations83
US8907087B2Dec 9, 2014
Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors
SIGNAL PHARM LLC4 citations83
US9556126B2Jan 31, 2017
Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC10 citations82
US9155736B2Oct 13, 2015
Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SIGNAL PHARM LLC16 citations82
US9156798B2Oct 13, 2015
Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC5 citations82
US9079900B2Jul 14, 2015
Methods of synthesis and purification of heteroaryl compounds
SIGNAL PHARM LLC5 citations82
US7442699B2Oct 28, 2008
Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
SIGNAL PHARM LLC10 citations82
US7354947B2Apr 8, 2008
Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof a JNK inhibitors and compositions and methods related thereto
SIGNAL PHARM LLC10 citations82
US9403829B2Aug 2, 2016
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
SIGNAL PHARM LLC13 citations81
US9359364B2Jun 7, 2016
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
SIGNAL PHARM LLC10 citations81
US8686135B2Apr 1, 2014
Methods of synthesis and purification of heteroaryl compounds
SIGNAL PHARM LLC8 citations81
US7119114B1Oct 10, 2006
Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto
SIGNAL PHARM LLC16 citations81
US9725450B2Aug 8, 2017
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC9 citations80
US9513297B2Dec 6, 2016
Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
SIGNAL PHARM LLC14 citations79
US7351729B2Apr 1, 2008
JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
SIGNAL PHARM LLC11 citations77
US11325890B2May 10, 2022
Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC2 citations72
US10975039B2Apr 13, 2021
Isotopologues of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
SIGNAL PHARM LLC1 citations72
US10940152B2Mar 9, 2021
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC1 citations72
US10689351B2Jun 23, 2020
Isotopologues of 2-(tert butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
SIGNAL PHARM LLC1 citations72
US10646493B2May 12, 2020
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC1 citations72
Showing the top 50 of 103 patents by PatentIndex Score.